Abstract: More than 130 radionuclides are being used worldwide for therapeutic, diagnostic, and preventative purposes in the medical field. Using radionuclides, different organs can be imaged, and malfunction revealed. The most commonly used radionuclide in diagnosis by SPECT is technetium-99m ( 99m Tc), with some 40 million procedures yearly, almost 80% of all nuclear medicine procedures in the world. The Positron Emission Tomography (PET) is sophisticated and more precise technique using isotopes, like 18 F produced in a cyclotron. The synthesis and use of organic molecules and their labeling with radionuclides are currently dominating in new radiopharmaceutical development. On the other hand inorganics ( 60 Co, 131 I and 192 Ir) are still playing unique role in nuclear medicine. In this article more commonly used radionuclides and their inorganic forms in nuclear medicine are described.
INTRODUCTION
In Nuclear medicine radiation is used to gain diagnostic information about the functioning of a patient's specific organs, or to cure them. The use of radionuclides in solution form began in the late 1930s with attempts to treat blood diseases such as polycythaemia vera with the aid of phosphorus-32 (  32 P) labeled sodium hydrogen phosphate [1] . At the same time, Iodine-131 ( 131 I) as sodium iodide was being trialled as a treatment for cancer of thyroid [2] . Using gamma (γ) emitting radionuclides, various organs such as thyroid, bones, heart, brain, liver, spleen etc, are imaged, and malfunction in organ revealed. Radiation is also used to cure diseased organs, or tumours. Over ten thousand hospitals worldwide use radionuclides in medicine, and about 90% of the procedures are for diagnostic purposes. The most common radionuclide used in diagnosis is technetium-99m ( 99m Tc); the daughter product of molybdenum-99 ( 99 Mo ). Approximately 40 million procedures are performed yearly, accounting for 80% of all nuclear medicine procedures worldwide [3] . Nuclear medicine was developed in the 1950s by physicians with an endocrine emphasis, initially using 131 I to diagnose and then treat thyroid disorder [4] . The Positron Emission Tomography (PET) is a sophisticatedand, more accurate technique using isotopes produced in accelerators. PET is a functional imaging technique that produces a three-dimensional (3-D) image of functional processes in the human body. PET's most important clinical role is in oncology, with fluorine-18 ( 18 F) as the prime radiotracer, since it has proven to be the most accurate non-invasive method of detecting and evaluating most cancers [5] . Several radionuclides have been developed and tagged into appropriate carriers for targeted radiotherapy and diagnosis. As radionuclide carriers, chelating chemical agents, monoclonal antibodies, peptides, biomolecules, biodegradable particles, colloids, etc., have been investigated as radiopharmaceuticals for therapeutic nuclear medicine. The synthesis and use of organic molecules and their labeling with different radionuclides are currently dominating in new radiopharmaceutical development [6] . On the other hand inorganics are still playing unique role in nuclear medicine [7] . Inorganics include metals, salts, compounds made from single elements and any other substance that don't contain carbon bonded to hydrogen. In this article more commonly used radionuclides and their inorganic forms in nuclear medicine are described. It includes decay characteristics, production mode and medical applications etc., of the radionuclides.
RADIONUCLIDES FOR DIAGNOSIS AND THERAPY
Radioisotopes are used in diagnostic studies via emission tomography (SPECT and PET). Diagnostic techniques use radiotracers which emit γ rays from within the body. These tracers are usually short-lived linked to chemical compounds which permit specific physiological functions to be checked. The radio labeled compounds are injected, inhaled or given orally. The first type is where single photons are detected by a γ-camera which can view certain organs from many different angles. In the second type a positron-emitting radionuclide is introduced, usually by injection, and accumulates in the target tissue. As it decays it emits a positron (β + ), which promptly combines with a nearby electron resulting in the simultaneous emission of two identifiable γ rays (511 keV) in opposite directions. These are detected by a PET camera and give very accurate indication of their origin.
The major criteria for the selection of a radionuclide for therapy are suitable decay characteristics and biochemical behavior. Regarding the decay properties, the desired half life is between few hours and several days; the emitted particles (β -, α, and Auger electron) of radiation should have an appropriate linear energy transfer (LET) value and range in the tissue. The ratio of target to non target tissue should be high.
Boron Neutron Capture Therapy
In 1935, Taylor and Goldhaber described that boron-10 ( 10 B) nuclei could capture thermal neutrons resulting in splitting of the boron-11 ( 11 B) nuclei into helium-4 (α particles) and lithium-7( 7 Li) ions [8] . In 1936, Locher, a scientist at the Franklin Institute in Pennsylvania, realized the therapeutic potential of the reaction and products and proposed that boron neutron capture could be used for the treatment of cancer [9, 10] . Sweet first suggested the discovery for the most malignant brain tumors in 1951 [11] , and a trial of the therapy against glioblastoma multiforme using borax (sodium borate) as the boronating agent was reported in a collaboration between Massachusetts General Hospital and Brookhaven National Laboratory in 1954 [12] .
Both α particles and 7 Li ions produce closely spaced ionizations in the immediate vicinity of the reaction, with a range of approximately 5-9 µm; the diameter of one cell. Their lethality is limited to 10 B containing cells.
Boron Neutron Capture Therapy (BNCT), therefore, can be considered as both a physically and biologically targeted type of radiation therapy. The success of BNCT is dependent upon the selective delivery of sufficient amounts of 10 B to the tumor with only small amounts localized in the surrounding normal tissues [13] . Various 10 B delivery agents have been synthesized [14] , but only two of these currently are being used in clinical trials. The first, primarily used in Japan is a polyhedral borane anion, sodium borocaptate or BSH (Na 2 B 12 H 11 SH), and the second is a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine (BPA). The BPA has been used in clinical trials in the United States, Europe, Japan, Argentina and Taiwan. Following administration of either BPA or BSH by intravenous infusion, the tumor site is irradiated with neutrons, the source of which has been specially modified nuclear reactors. Up to 1994, low-energy (< 0.5 eV) thermal neutron beams were used in Japan [15] , but since they have a limited depth of penetration in tissues, higher energy (>0.5eV<10 keV) epithermal neutron beams, which have a greater depth of penetration, have been used in clinical trials in the United States [16, 17] , Europe [18, 19] , and Japan [20, 21] . Boron containing nano particles and boron carbide particles delivery agents has also been evaluated [22] .
The BNCT is a highly selective type of radiotherapy that can target the tumor at the cellular level without causing radiation damage to the adjacent normal tissues. By BNCT doses up to 60-70 Gy can be delivered to the tumor cells in one or two applications compared to 6-7 weeks for conventional external beam photon irradiation.
Cesium-137
The half life of Caesium-137 ( Cs is ~ 6% by fission reaction of various isotopes of thorium, uranium, and plutonium [23] . Generally 137 Cs is produced by fissioning uranium-235 ( 235 U) nuclei and then chemically separating the cesium from the irradiated nuclear fuel or targets. Separated 137 Cs sold internationally is produced only by the Production Association Mayak (PA Mayak) in the Chelyabinsk region of Russia and sold through REVISS; a U.K.-based company [24] . It is supplied as cesium chloride, a crystalline salt. Cesium-137 teletherapy units are designed for treatment of different source to skin distances (SSD) [25] .
Radioactive sealed sources of 137 Cs as CsCl are manufactured either as an insoluble powder, ceramic microspheres or a solid ceramic rod. The radioactive material is then doubly encapsulated in stainless steel, with each layer welded shut.
Cr are practiced. The first one is the direct neutron bombardment of enriched or natural 50 Cr(n,γ) 51 Cr [29] , while the second one is based on Szilard-Chalmers reaction using specially chosen chromium compounds [30, 31] . Sodium chromate ( 51 Cr) is useful for determining red blood cell (RBC) volume or mass, studying RBC survival time (in conditions such as hemolytic anemia), and evaluating blood loss [32] . The suggested dose range in the 70 kg patient for determination of RBC volume or mass is 0. 37 Co sealed sources used in previous models [35] . Cobalt-60 teletherapy machines provide relatively high energy γ rays for therapy which are ideally suited for treatment of head and neck carcinomas and other superficially located tumors, such as breast cancers and soft tissue sarcomas of extremities. 60 Co sources are not adequate for treatment of deep seated tumors and have the added disadvantage of decreasing output with decay of source and the need for source replacement within 5-7 years, due to 5.27 y half-life of 60 Co.
In 1962 Walstam [36] introduced the first concept of a remote afterloader equipped with 60 Co. Since its introduction, 60 Co has achieved tremendous success and has continued to evolve to support modern HDR brachytherapy needs. Cobalt-60 has been shown to be a good choice for treating gynecological, rectal, prostate, breast, esophagus, skin, and other body sites [37] [38] [39] [40] [41] . The treatment with 60 Co leads to lower dose to organs at risk (OAR) than with 192 Ir. Due to its higher mean energy of 1.25 MeV, less backscatter is produced and therefore, 60 Co shows a more linear radial dose function than 192 Ir with 0.37 MeV. Due to the long half-life of 60 Co, the source can be used for up to 5 years which means that during the recommended working life of a single 60 Co source, approximately 20 source exchanges of 192 Ir would have to be performed.
Copper-64
Copper-64( [46] . Currently nanodevices/nanoparticles [47] have been used in biomedical field investigating new and improved diagnosis and therapy agents and with sufficient development, the 64 Cu is likely to become an important radionuclide in nuclear medicine in coming years. widespread. Iodine-124 has potential as both a diagnostic and a therapeutic radionuclide. The main use of iodine-124 is to directly image the thyroid using positron emission tomography [59] . Iodine-124 can also be used as a PET radiotracer with a usefully longer half-life compared with fluorine-18. In this use, the nuclide is chemically bonded to a pharmaceutical to form a positron-emitting radiopharmaceutical, and injected into the body, where again it is imaged by PET scan (60) (61) (62) .
Fluorine-18
The best nuclear reaction for the production of 124 
Iodine-125
Iodine-125 ( 125 I) has a physical half-life of ~60d, and disintegrates by 27-32 keV Te X rays and 35 keV γ ray). It is a radionuclide of iodine, which has major uses in biological assays (e.g., radioimmunoassay-RIA) and as a radioactive sealed source in radiation therapy as brachytherapy (prostate and brain tumors treatment). The neutron irradiation of 124 Xe by n,γ reaction produces 125 I in a nuclear reactor. The separation of Xe and I is carried out by dry distillation technique [64] . Due to better radiation penetration and shorter half-life I is preferred over 125 I for thyroid imaging. In addition to its use in biological assays [65] , 125 I is generally used by radio-oncologists as brachytherapy to treat cancer at sites other than the thyroid, such prostate cancer and brain tumors [66, 67] . When the radioactive sealed source of 125 I is used in therapy, it is encapsulated in titanium (Ti) seeds and implanted in the area of the tumor, where it remains. The low energy of the γ spectrum of 125 I limits radiation damage to tissues far from the implanted seeds.
Iodine-125 was finally introduced in interstitial cancer therapy, such as prostate, lung cancer and lymph nodes in 1965 [68] . Since 1979 it has been applied for treatment of brain tumours. Even though the physical and biological characteristics make 125 I implants quite attractive for minimal invasive treatment damages, the place for stereotactic brachytherapy is still poorly defined [69] .
Iodine-131
Iodine MBq (4 to 10 mCi) for the treatment of hyperthyroidism, [72] . Higher doses may be effective for the treatment of toxic nodular goiter and other peculiar situations. For thyroid carcinoma, the usual sodium iodide-
131
I solution therapeutic dose is 3700 to 5550 MBq (100 to 150 mCi) [73] .
The post-operative residual thyroid tissue ablation is performed by a usual dose of 1850 MBq (50 mCi) [74] . and emits β -particles of maximum energy of 672 keV (46%) and γ rays of energies of 604, 468 and 308 keV. The iridium (>99.9 % purity) target is irradiated in a high flux reactor, providing more than 2x 10 14 n.cm
.sec -1 neutron flux density, because specific activity of the irradiated target should be more than 16.8-18.5 TBq/g (450-500 Ci/g). Activity of the 192 Ir HDR assembly should be more than 370 GBq (10 Ci) for effective therapy [78] . Low dose rate 192 Ir is manufactured in lengths of wire 10-14 cm long and 0.3 mm thick, which can be cut into the desired length for LDR applications. The wires are flexible and inert to body fluid.
The HDR 192 Ir sources are composed of platinum/iridium alloy having a 3.5 mm long, 0.6 mm diameter with a high specific activity of 192 Ir. It is coated in 1 mm of platinum, which attenuates any electrons emitted through decay. This capsule is welded to the end of a wire that allows it to be retracted and deployed from within a High Dose Rate remote afterloading device. Iridium-192 HDR brachytherapy is a suitable alternative in the treatment of localized prostate cancer who are not eligible for radical prostatectomy [79] .
Traditionally, High Dose Rate after loaders have been based on Ir-192. The high specific activity of iridium allowed very small sources to be used interstitially despite its half-life period. Typically a source exchange is required each 3-4 months to keep the treatment times within the limits required by clinical practice and also because a maximum number of transfers is recommended by the manufacturer. The Cobalt-60 manufacturer claims important economic advantages because of the larger half-life period and the improved technology which allow for less source exchange frequency [80] . The Brachytherapy treatment may improve the control of local tumor and prolong the survival of patient, when used in deep malignant brain gliomas, by temporary implanted high doses of 192 Ir radioactive sealed sources [81] .
Catheter-based brachytherapy using 192 Ir seeds has shown valuable reduction in the rate of restenosis in patients with coronary in-stent restenosis [82] .
Women with locally advanced or recurrent gynecological malignancies treated with the remote afterloader LDR MUPIT applicator can expect reasonable rates of local control that are not operatordependent [83] .
According to published reports, fractionated HDR brachytherapy represent one option for the primary treatment of cervical carcinoma [84] .
Krypton-81m
Krypton-81m ( 81m Kr) has a half-life of 13 sec and is a gas produced from the decay of rubidium-81 ( 81 Rb is the proton reaction of natural krypton [86] . 81 Rb solution having certain concentration is fixed on to AG50W-X8 cation exchange column. The cation resin has a high affinity for Rb, while the daughter 81m Kr is eluted by sterile air or sterile water. In the case of water, an adjustment is made with a sodium chloride solution of appropriate concentration [87] . 81 Rb/ 81m kr generators are used either in gaseous form for ventilation imaging or in solution for lung perfusion imaging.
The short half-life of 13 sec implies that inhaled 81m Kr disappears from the alveolar space at a much faster rate by decay than by exhalation. When a patient is breathing air with 81m Kr at a normal respiratory rate,
Kr concentration is at steady state, closely proportional to regional ventilation. Deviation from proportionality occurs in lung compartments with very high or low regional ventilation in relation to resident alveolar volume [88] . This deviation occurs in children with a high ventilatory rate and a high ventilation/volume ratio [89] . During steadystate 81m Kr ventilation, multiple planar imaging or SPECT acquisition can be performed. Very recently, Ventilation/Perfusion SPECT in combination with lowdose CT has been reported [90] . 81m Kr has an advantage that ventilation and perfusion can be imaged simultaneously as 81m Kr has higher γ energy of 193 keV than technetium-99m ( 99m Tc) of140 keV, which is used as a perfusion marker [91, 92] . As 81 Rb has a short half-life of only 4.6 h, the 81 Rb/ 81m kr generator can be used for 1 day only. Very low radiation exposure to patients makes 81m Kr an alternative to radioactive aerosols and particularly advantageous for use in young children [88] .
Nitrogen-13
The physical half-life of Nitogen-13 ( 13 N) is 9.96 min, hence application is limited and requires an onsite cyclotron production technology. Nitrogen-13 decays by only positron emission (100%) to stable carbon-11 ( MeV. There are several charged particle reactions leading to the production of 13 N [93] . The widely used production route is the 16 O(p, α) 13 N reaction on water using 16.5 MeV protons [94] [95] [96] . Over the past 3 decades 13 N labeled ammonia has been used for most of the scientific investigations in cardiac PET imaging. Intravenous injection, typically 10-20 mCi (370-740 MBq) as a bolus is useful in these studies [97, 98] . Two methods are commonly used for 13 N-ammonia synthesis. In the first method, the 13 N-labeled nitrates/nitrites formed by proton irradiation of water are reduced by either titanium (III) chloride, titanium (III) hydroxide, or Devarda's alloy (an alloy of aluminum 44-46%, copper 49-51%, and zinc 4-6%) in alkaline medium [99] . After distillation, trapping, and sterile filtration, 13 N-ammonia is available for injection. In the second method, oxidation of 13 N to 13 N-nitrates/nitrites is prevented by the addition of ethanol as a scavenger to the target content [100] . The target content is passed through a small cation-exchange column to trap 13 Nammonium ions, and 13 N-ammonia is then eluted with physiological saline and filtered through bacteria filter before its use.
Oxygen-15
Oxygen-15 ( Oxygen-15 disintegrates to stable 15 N. Various charged particle reactions leading to the production of 15 O have been described [101] . Oxygen-15 is commonly produced using a deuteron particle reaction on N gas or a proton particle reaction on enriched 15 N gas.
water has also been produced by bombarding natural water using the 16 O(p, pn) 15 O route, with a final purification on an ion exchange column [102] . Oxygen-15 water is a freely diffusible agent with very high myocardial extraction across a wide range of myocardial blood flows [103] . The degree of extraction is independent of flow and is not affected by the metabolic state of the myocardium. Since oxygen is a freely diffusible tracer, but imaging is challenging due to its high concentration in the blood pool.
Palladium-103
Palladium-103 ( 103 Pd) has a 17-day half-life and Xray photon emission at the main energies of 20.07 keV (19.83%), 20.22 keV (37.55%) and 22.71 keV (37.55%) [104] . 103 Pd is commonly produced by cyclotron irradiation of rhodium targets with accelerated protons. This approach allows production of carrier-free 103 Pd having near theoretical value of specific activity of 75000 Ci/g (~2. 8 10 6 GBq/g) [105] .
An alternative approach to 103 Pd production is reactor irradiation of isotopically enriched 102 Pd.
The low natural isotopic abundance of 102 Pd
(1,02%) requires the use of moderate to highly enriched 102 Pd target material of no less than 50%.
Moreover, the low cross-section of 102 Pd(n,γ) 103 Pd nuclear reaction (thermal cross-section is 3.4 barn, resonance integral 10 barn) requires also the use of highflux nuclear reactors, like the HFIR (ORNL, OakRidge, USA) or SM (RIAR, Dimitrovgrad, Russia), to produce high-specific activity 103 Pd [105] . The effectiveness of 103 
Radium
Radium (Ra) has thirty three known nuclides, with mass numbers from 202 to 234 and all are radioactive [119] . Four radionuclides occur naturally in the decay chains of thorium-232, uranium-235, and uranium-238. These are 223 Ra (half-life=11.4 days), 224 Ra (halflife=3.64 days), 226 Ra (half-life=1600 years), and 228 Ra (half-life=5.75 years). Radium-226 is the most long lived radionuclide of Ra, which has a half-life of 1600 years and disintegrates into radon gas. In nature, radium is found in uranium and thorium ores in trace amounts as small as a seventh of a gram per ton of uraninite. In 1898 Marie Curie and Pieree Curie discovered Ra in the form of radium chloride [120] . Natural radium mostly comprises 226 Ra and emits mostly α particles, but other steps in its decay chain (the uranium or radium series) emit α or β -particles, accompanied by γ rays [121] . The biological effects of radium were known to some extent from its discovery. Antoine Becquerel became ulcerated by carrying a small ampoule of radium in his waistcoat pocket for 6 hours. Pierre Curie observed skin lesion when attached a tube filled with radium to his arm for 10 hours. These observations raised the question that if Ra can destroy healthy tissue, could it also destroy cancerous tissue [122] ?
Kelly, physicians of Johns Hopkins Hospital, a major pioneer used Ra for the treatment of cancer [123] . In 1906, Kelly treated his own aunt but she died shortly after surgery [124] . He used excessive amounts of Ra to treat various tumors and cancers, resulting in the deaths of some of his patients due to high doses of Ra [124] . Kelly inserted a Ra capsule near the affected area then sewed the radium "points" directly to the tumor [125] . Similar technique was used to treat Henrietta Lacks, the host of the original HeLa cells, for cervical cancer [126] . Radium chloride or bromide was commonly used to produce radon gas which was used as a cancer treatment and several of such radon sources were used in Canada during the 1920s and 1930's [127, 128] .
Several treatments that were performed in the early 1900s are not used anymore because of the harmful effects like, anaemia, cancer, and genetic mutations caused by RaBr exposure [129] . Now-a-days 223 Ra and 224 Ra are used as therapeutic agents. Radium-223 dichloride is an α emitter used in the treatment of patients with prostate cancer that is resistant to medical or surgical treatments. This type of cancer lower testosterone and has spread to only bones with symptoms. Radium-223 dichloride is given intravenously slowly, over about 1 minute. The drug mimics calcium (Ca) and forms complexes with the bone mineral at sites of bone metastatses. It then emits α particles, causing the DNA destruction in nearby cells, resulting death of cancer cells in the bone. Radium-223 acts as an internal radiotherapy treatment agent. It is a mildly radioactive and commercially sold by the name of Alpharadin and now has the brand name Xofigo [130] .
Although 223 Ra is generated in trace amounts by the disintegration of 235 224 Ra has a half-life of 3.2 days and has been used for many decades to treat ankylosing spondylitits [132] . Recently in Germany, it has been reintroduced and reapproved for ankylosing spondylitits [132] . In the case of 224 Ra, long term follow up of patients receiving moderate levels revealed no significant difference in overall cancer incidence or life expectancy compared to a control population [133] . Radium-224 is a natural daughter product in the decay chain of natural 232 Th to 228 Th [134] .
Brachytherapy can be traced historically with applications of 226 Ra sources, which involved exposure of the surrounding tissue. Treatment of oral tongue carcinoma has been quite successful when treated with radiation therapy particularly by interstitial brachytherapy [135] . To make comparison simple, the patients treated by one of the three major sources, 226 Ra, 192 Ir and MS-HDR ( 192 Ir) were examined.
Rhenium-186
Rhenium-186 ( 186 Re) has a physical half-life of 3.7 days and it emits a β -particle with a a mean energy of 349 keV, maximum energy of 1070 keV, and an average soft tissue range of 1.1 mm. 186 Re also emits 9% abundant γ emission of 137 keV. In a nuclear reactor low specific activity 186 Re can be made available from neutron irradiation of 185 Re [136] . Proton or deutron bombardment of enriched tungsten targets can produce high specific activity 186 Re [137] [138] [139] .
The use of Re-186-labelled sulfur colloid particles for therapy of rheumatoid arthritis of the synovial joints is quite successful. 186 Re sulpfur colloid is suitable for hip, shoulder, elbow, wrist, ankle and subtalar joints.The administered activity and the injected volume of 186 Re sulfide colloid depends on the volume of the joint to be treated [140] . The maximum activity of 186 Re at a single session should be ~ 370 MBq (10 mCi). The use of Re-186-liquid-filled balloons for restenosis therapy has also been evaluated [141] . Rhenium-186-labelled particles are sold commercially in European countries and the supplier recommends 186 Re sulfide colloid, for radiosynovectomy of medium size joints [142] .
Rhenium-188
Rhenium-188 ( 188 Re) has a half-life of 16.9 h and emits a β -particle with a maximum energy of 2.12 MeV, useful for therapeutic applications. It also emits a 155 keV gamma photon (15%) for gamma camera imaging.
Rhenium-188 can be produced with high specific activity by neutron irradiation of enriched 187 Re in a nuclear reactor [143] . However carrier-free 188 A simple method for preparation of Re-188-labelled sulfur colloid is reported [145] , which provides a tight particle size range of 86% = 5 µm. The most activity is retained in the liver via intravenous or hepatic artery injection. Rhenium-188 sulfide preparations have shown usefulness when injected in tumors and used in radiosynovectomy [146, 147] . 188 Re sulfide colloid is commercially available for radiosynovectomy of large size joints [142] .
Re
Re-188-labelled agents for the use of 188 Re liquidfilled angioplasty balloons inflated at low pressure following coronary angioplasty for the inhibition of coronary restenosis by high dose delivery have been evaluated [148, 149] . Angioplasty balloons are filled at low pressure (2-3 atmospheres of inflation pressure) with a solution of 188 Re-perrhenate or Re-lSS-MAG 3 following high pressure angioplasty to deliver a dose of 2500-3000 rad at 0.5 mm of depth. Patient studies have been performed at several Institutions in the USA, Europe and Australia.
For vascular radiation therapy or for other applications which require a 188 Re liquid-filled balloons, the pooled experience obtained thus far from several collaborative clinical sites, a total volume of 1.5-2 mL of the rhenium-188 solution with a specific volume (up to 250 mCi/mL) which is required for use in the Catheterization Laboratory. Although the actual balloon volume will probably not be greater than 0.15 -0.20 mL even for large coronary vessels, the extra volume is required for filling the lines, valves, etc., and to have sufficient back pressure in the inflation syringe [150] .
Rubidium-82
The half-life of strontium-82 ( 82 Sr 82 Rb decays 95.5% by β + emission, resulting in the production of annihilation radiation of two 511 keV γ rays; and 4.5% by EC, resulting in the emission of "prompt" γ rays of predominantly 0.777 MeV. Both decay modes of 82 Rb lead to the formation of stable 82 Kr nuclide. The only useful charged particle reaction for the production of 82 Sr using protons is the high energy reaction of metallic rubidium target material 85 Rb(p, 4n) 82 Sr [152] .
The 82 Sr can also be produced in an accelerator by proton spallation of molybdenum (Mo) with a highenergy 800 MeV proton accelerator, followed by chemical purification technique [153] . Cardiogen-82 generator system contains accelerator-produced 82 Sr fixed on stannic oxide column properly shielded by lead (Pb) provides nonpyrogenic solutions of 82 Rb chloride for injection purposes [154] . The 82 Rb is eluted with 25-50 mL physiological saline (0.9% NaCl) by a computercontrolled elution pump, connected by Intravenous tubing to the patient. The 82 Sr/ 82 Rb generator is fully replenished every 10 minutes and 90% of available activity of 82 Rb can be eluted within 5 minutes since the last elution, making serial imaging every 5 minutes. Rubidium-82 has proven an efficient heart imaging agent for routine clinical usage [155, 156] . The recommended adult single dose of 82 Rb-chloride injection is 1480 MBq (40 mCi) with a range of 1110-2220 MBq (30-60 mCi) . Rubidium is analogous to potassium ion (K + ) in its biochemical behavior and is rapidly extracted by the myocardium proportional to the blood flow. Rubidium cation participates in the sodiumpotassium (Na + /K + ) ion exchange pumps that are present in cell membranes. The intracellular uptake of 82 Rb requires maintenance of ionic gradient across cell membranes. Rubidiumb-82 radioactivity is accumulated in viable myocardium reflecting intracellular retention, while the radiotracer is cleared rapidly from necrotic or infarcted tissue [154] .
Strontium-89
Strontium-89 ( Y(n,p) 89 Sr reaction. Low specific activity 89 Sr can also be produced via 88 Sr(n,γ) 89 Sr reaction in a reactor [157] . Following intravenous injection of 89 SrCl 2 behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. 89 SrCl 2 is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, more than 50% injected radioactivity is retained in the bones. Uptake of Sr by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of Sr than surrounding normal bone. 89 Sr is commercially available as a pharmaceutical brand name Metastron™ and is used as a bone pain palliation agent [158] . 90 Sr from fission products have been described [159] . After 1 year of decay of burnt fuel rods, 90 Sr represents 3.7% by mass of the total fission product inventory. Typically, 90 Sr is combined with fluorine or chlorine to produce strontium fluoride ( Strontium-90 is a bone seeking element, similar to calcium. After entering the organism, approximately 70-80% of the 90 Sr gets excreted. Only 1% activity remains in blood and soft tissues, while all remaining strontium-90 is deposited in bones and bone marrow [160] . 90 Sr radioactive sealed sources are prepared as a plaque -usually a silver disc coated in 90 Sr. The disc is placed in a cavity within a Pb larger disc, and a very thin metal 'window' covers its external surface.
Strontium-90 can also be used for endovascular brachytherapy, but typical use is in ophthalmic applicators for the treatment of pterygium [161, 162] .
The safety and efficacy of strontium (Sr 90 ) beta radiotherapy as adjuvant treatment for conjunctival melanoma has been reported [163] .
Technetium-99m
Technetium -99m ( 99m Tc) has a half -life of 6 h and only emits 140 keV gamma ray, which is quite suitable for gamma cameras imaging. It is currently the most widely used radionuclide in diagnostic nuclear medicine. For the last 5 decades, it has dominated over all other nuclides used in nuclear medicine. 99m Tc is the daughter product of 99 Mo (T 1/2 = 67 h) which can be obtained with low specific radioactivity either by irradiation of natural 98 Mo (usually as MoO 3 ) with thermal neutrons in a nuclear reactor [164] or with high specific activity from fission of 235 U, also in a nuclear reactor [165] . The majority of the world's supply of 99m Tc is derived from 99 Mo/ 99m Tc generators in which fission-produced 99 Mo is adsorbed to a small alumina column. These generators are can be eluted with small volumes of physiological saline to yield highly concentrated solutions of very pure 99m Tc [166] . Other separation techniques like, solvent extraction, sublimation, gel technology etc, were employed for isolation of 99m Tc from low specific activity 99 Mo.
Technegas
Technegas is an ultra-fine suspension of carbon micro-particles labeled with 99m Tc. A specially designed device called Technegas generator is employed for generation of technegas. In the generator a solution of sodium pertechnetate (Na 99m TcO 4 ) is introduced into a crucible and evaporated till dryness. In an inert atmosphere of argon gas technegas is generated by heating crucible to 2550 °C. The Technegas particles are hexagonal platelets of metallic 99m Tc closely encapsulated with a thin layer of graphite. The size distribution of technegas particles being around 30-60 nm with 80% of the particles being <100 nm. Technegas should be administered to the patient within 10 minutes of its preparation [167] . Once technegas inhaled by the patient the gamma camera is used for imaging in the ventilation part of a Ventilation/Perfusion SPECT scan. Technegas penetrates to the subsegmental areas of the lung and is trapped by surfactant in the alveolar walls. Lung Scintigraphy has a superior sensitivity combined with adequate specificity and low rate of non-diagnostic tests. The low radiation dose, the possibility to quantify the degree of embolism and to use the test for follow-up of treatment of pulmonary embolism and its feasibility in very sick patients, contributes to the priority of lung scintigraphy over Computed Tomographic Pulmonary Angiography [168, 169] .
Technetium-99m Labelled Colloidal Particles
Technetium-99m labelled colloidal particles, such as Tctin colloid have been used for lymphoscintigraphy and/or sentinel lymph node (SLN) detection purposes. Technetium-99m labelled colloids slow elimination rates from the injection site and the uptake of radioactivity by lymph nodes is dependent on both particle size and the functional state of the reticuloendothelial system.
Technetium-99m-antimony trisulphide colloid prepared by slowly adding a solution of potassium antimonyl tartrate to a hot saturated aqueous hydrogen sulphide solution has a particle size of 3-30 nm [170, 171] .
99m Tc-antimony trisulphide colloid provides satisfactory lymph node scans [170] [171] [172] , but several adverse reactions requiring medical treatment have been reported [173] . Tc-sulphur colloid ( 99m Tc-SC)
produced by the reaction of thiosulphate with acid is unsatisfactory for lymphoscintigraphy because of the relatively large particle size and range (100-1000 nm), thus, 99m Tc-SC produced by is filtered through a 0.1-0.2 µm filter to obtain particles of smaller and even sizes, commonly used in clinical studies [174] . Tcsulphur colloid produced by passing hydrogen sulphide gas through an acidic pertechnetate solution, produces particle sizes of less than 100 nm, and the product provides satisfactory lymph node scans [175, 176] .
Technetium-99m ( 99m Tc) rhenium sulphide nanocolloid is used for lymphoscintigraphy for the purpose of visualising the regional lymphatic system. It can be used for imaging and intraoperative detection of sentinel lymph node (SLN) in the breast cancer, prostate cancer, malignant melanoma, and carcinomas of vulvar, penile, and head and neck squamous cell. Imaging of regional lymphatic flow for individualised radiotherapy and lymphatic flow scintigraphy are performed for diagnosing lymphatic oedema in the limbs. It is also used in digestive exploration; gastroesophageal imaging. Subcutaneous injection is route of administration of 99m Tc-colloidal rhenium sulphide, generally in the interdigital space of the hand or foot, or in the marginal area of a tumour.
Since colloids are made of small size, they can be rapidly taken up from interstitial fluids into the lymph capillaries having a discontinuous wall with pores and no basal membrane. Some of the colloidal particles are phagocytosed by bordering cells of the reticuloendothelial system during transport of the lymph through the lymph nodes. This process is repeated from one lymph node to the next lymph node. It is a metal colloid, which is partly phagocytosed and stored in the first lymph node group. Following administration, the radioactivity in the lymph node corresponds to 3.06 ± 0.10 % of the injected radioactivity at the first hour, and 3.83 ± 0.16 % at the third hour [177] . Rhenium sulphide nanocolloid comprises of two vials. One contains: Rhenium (as sulphide): 0.15 mg; Gelatin: 9.6 mg; Ascorbic acid: 7 mg; Water for injection: 1 mL, whereas second vial contains: Sodium pyrophosphate: 3 mg; Stannous chloride dihydrate: 0.1 mg [178] . Tc-Sn colloid has been used for liver and spleen scintigraphy [179, 180] . When injected, 99m Tc colloidal tin circulates in the blood and accumulates in the liver and the spleen. An image will then help doctor to determine the ability of these organs to eliminate foreign material like bacteria and denatured protein from the blood.
The particle size of 99m Tc-tin colloid is dependent on the ratio between the 99m Tc solution and the tin solution [181] . As the ratio of tin decreases, the size of colloidal particles increases. Technetium-99m-tin colloid has a particle size of 50-1500 nm. Uenosono Tc-PYP has been used as a blood pool imaging useful for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15-30 minutes prior to intravenous injection of Na 99m TcO 4 for in vivo red blood cell labeling, ~ 75% of the injected radioactivity is found in the blood pool. The modified in vivo/in vitro red blood cell labeling method has also been utilized for blood pool imaging [189, 190] .
Thallium-201
Thallium-201 ( The most common route however is the 203 Tl (p, 3n) 201 Pb →
201
Tl reaction on enriched 203 Tl. The optimum proton energy range for production is 28 →20 MeV, Therefore a medium-energy 30 MeV proton is needed. The production of no-carrier-added 201 Tl via irradiation of 203 Tl or nat Tl involves a 2-step process and complex wet chemical processing. At first 201 Pb is separated from the target matrix activity. Thereafter 201 Pb is allowed to decay for an optimum time of 32 h whereby 201 Tl grows in. The removal of the 201 Tl can be performed by anion-exchange chromatography or solvent extraction techniques [191] .
Thallous chloride ( 201 Tl) is indicated in myocardial perfusion imaging for the diagnosis and localization of myocardial infarction [192] [193] [194] [195] .
Thallous chloride ( 201 Tl) is also indicated in studies of myocardial perfusion done under resting conditions and after physiologic or pharmacologic stress induced by exercise or infusion of dipyridamole, adenosine, or dobutamine respectively, to detect myocardium with abnormal perfusion reserve secondary to coronary artery disease [196] [197] [198] [199] [200] .
Thallous chloride ( 201 Tl) is used for the detection and localization of parathyroid tissue in patients with documented hyperparathyroidism. Thallous chloride ( 201 Tl) may also be useful in preoperative screening to localize extrathyroidal and mediastinal sites of parathyroid tissue and for postsurgical reexamination [201] [202] [203] . However, the use of thallous chloride ( 201 Tl) as a parathyroid imaging agent generally has been replaced by technetium Tc-99m sestamibi.
Thallous chloride ( 201 Tl) is used for the detection and localization of various tumors, including thyroid carcinomas, malignant brain neoplasms, lymphomas, and mediastinal tumors, especially for postoperative detection of residual and recurrent tumors and differentiation of these from post-therapy fibrosis or necrosis [204] [205] [206] [207] [208] .
Usual adult and adolescent administered activity (IV) are 37-74 MBq (1-2 mCi) and 74-148 MBq (2-4 mCi) for Planar and SPECT imaging, respectively. Parathyroid imaging is performed by injecting 75 MBq (2 mCi) and tumor imaging by 55.5 -111 MBq(1.5-3 mCi) Usual pediatric administered activity for Cardiac imaging andParathyroid imaging is1.11 MBq (30 µCi) per kg of body weight administered intravenously, with a minimum total dosage of 27.75 MBq (750 µCi) and a maximum total dosage of 111 MBq (3 mCi).
In Cardiac imaging, the Thallous chloride ( 201 Tl) appears to accumulate in cells of myocardium and other tissues in a manner analogous to that of potassium [209] . The initial biodistribution of Thallous chloride ( 201 Tl) in most tissues is primarily related to regional blood flow. Ischemic myocardial cells take up less 201 Tl than nonischemic cells, in proportion to the relative change [202, 203] in blood flow, especially during maximal stress (or pharmacologically induced vasodilation) when the differential in perfusion is most marked between regions supplied by normal coronary arteries and those supplied by stenotic vessels. Imaging equipment can record regional differences in thallium-201 uptake, and thus in myocardial perfusion, confirming the presence or absence of coronary disease [210, 211] In Parathyroid imaging, the Thallous chloride (  201 Tl) localizes in parathyroid adenomas, parathyroid hyperplasia, and other abnormal tissues, generally in proportion to organ blood flow at the time of injection [212] .
Two other Technetium-99m labeled compounds MIBI and tetrofosmin are also used for same purpose. Usually MIBI/tetrofosmin labeled with 10-30 mCi of technetium-99m is injected to patient. Tc-tetrofosmin requires two injections, a stress study and a rest study. While only one injection of (~2mCi) 201 TlCl is sufficient for whole study. 90 Y deposition [216] [217] [218] .
Finally, for patients with rheumatoid arthritis (RA) that is unresponsive to glucocorticoids, nonsteroidal anti-inflammatory pharmaceuticals and diseasemodifying antirheumatoid pharmaceuticals, cronicoligo or mono-arthritis can be cured by radionuclide synovectomy. Radiosynoviorthesis with 90 Y is an established concept for the treatment of persistent synovitis of the knee joint [219, 220] .
Radiolabeled particles of various sizes have been applied for delivering a high localized radiation dose to tumors in different organs following intraarterial administration for more six decades [221] . Delivery of a highly selected distribution of radiation doses that are 20-30 times greater than that achievable by external beam therapy is possible by virtue of the preferential blood flow to the tumor relative to normal tissues [222] . 
Xenon-133
Xenon-133 ( . Xenon-133 gas has been shown to be useful for diagnostic inhalation studies for the evaluation of pulmonary function, for lungs scanning and applied to assessment of cerebral blood flow.
Xenon-133 is a readily diffusible gas which is not utilized by the body. It passes through cell membranes, freely exchanges between blood and tissue, and tends to concentrate more in body fat than in blood, plasma, water or protein solutions. Xenon-133 gas is administered by inhalation from a spirometer or closed respirator device. The usual activity range employed for inhalation by an average patient of 70 kg is 74 to 1110 MBq (2 to 30 mCi) for pulmonary function including imaging and 370 to 1110 MBq (10 to 30 mCi) for cerebral blood flow studies [227, 228] . 133 Xe is historically an agent that was used for ventilation studies [229] .
CONCLUSIONS

Sodium iodide (
131 I) treatment of thyroid disorders is the only treatment that has continued to be developed up to the present day and has become fully established in routine clinical practice in developing as well as in developed countries. Some other radionuclides, such as 22 Na, 35 S, 59 Fe, 85 Sr, radioindium and 198 Au find rare medical applications in routine. Use of radioactive sealed sources ( 60 Co, 192 Ir and short lived radionuclides) will continue to play their important role in medical applications and even increase in the future. In the wake of the terrorist attack on September 11 th 2001 in USA, there is a security concern over sealed sources of cesium-137 as CsCl especially susceptible to be being used by terrorists. 
